AKEBIA THERAPEUTICS, INC. Shareholders' Equity
AKEBIA THERAPEUTICS, INC. (AKBA) had Shareholders' Equity of $25.02 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $25.02M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $27.38M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $32.61M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $41.59M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $25.02M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $27.38M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $32.61M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $41.59M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $29.22M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $24.58M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | -$49.19M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | -$50.40M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | -$33.75M 10-Q · filed 2025-11-10 | |
| 2024-03-31 | -$27.26M 10-Q · filed 2025-11-10 | |
| 2023-12-31 | -$30.58M 10-K · filed 2026-02-26 | |
| 2023-09-30 | -$39.42M 10-Q · filed 2024-11-07 | -$39.42M 10-Q · filed 2023-11-08 |
| 2023-06-30 | -$26.80M 10-Q · filed 2024-11-07 | -$26.81M 10-Q · filed 2023-08-28 |
| 2023-03-31 | -$19.12M 10-Q · filed 2024-11-07 | -$14.35M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $5.23M 10-K · filed 2026-02-26 | $9.34M 10-K · filed 2023-03-10 |
| 2022-09-30 | $8.26M 10-Q · filed 2023-11-08 | $13.85M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $58.94M 10-Q · filed 2023-11-08 | $62.30M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $22.58M 10-Q · filed 2023-11-08 | $26.12M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $74.01M 10-K · filed 2024-03-14 | $76.46M 10-K · filed 2022-03-01 |
| 2021-09-30 | $137.15M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $174.63M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $213.89M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $244.35M 10-K/A · filed 2023-08-28 | $247.62M 10-K · filed 2021-02-25 |
| 2020-09-30 | $317.96M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $370.26M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $396.36M 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $392.88M 10-K/A · filed 2023-08-28 | $394.76M 10-K · filed 2020-03-12 |
| 2019-09-30 | $467.56M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $519.36M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $566.38M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $635.93M 10-K · filed 2022-03-01 | |
| 2018-09-30 | $142.54M 10-Q · filed 2019-11-12 | $142.54M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $165.92M 10-Q · filed 2019-11-12 | $165.92M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $197.10M 10-Q · filed 2019-11-12 | $197.10M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $122.57M 10-K · filed 2021-02-25 | $119.33M 10-K · filed 2018-03-12 |
| 2017-09-30 | $99.88M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $57.00M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $30.62M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $68.12M 10-K · filed 2020-03-12 | |
| 2016-09-30 | $100.71M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $133.29M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $167.76M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $131.00M 10-K · filed 2019-03-26 | |
| 2015-09-30 | $145.41M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $149.75M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $94.61M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $104.08M 10-K · filed 2018-03-12 | |
| 2014-09-30 | $113.61M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $121.55M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $127.87M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | -$127.07M 10-K · filed 2017-03-06 | -$127.07M 10-Q · filed 2014-05-12 |
| 2012-12-31 | -$59.59M 10-K · filed 2016-03-14 | |
| 2011-12-31 | -$48.19M 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |